Chemoimmunotherapy of small cell bronchogenic carcinoma with VP-16-213, ifosfamide, vincristine, adriamycin, and Corynebacterium parvum
Thirty-five consecutive patients with small cell bronchogenic carcinoma (SCBC) received chemoimmunotherapy with VP-16-213, Ifosfamide, vincristine, Adriamycin, and Corynebacterium parvum. Of 33 evaluable patients, 26 (79%) responded with complete (55%) or partial (24%) remissions. Complete remissions were more common among patients with limited disease (11/14 patients, 79%) compared with those with extensive disease (7/19 patients, 37%) and among patients (11/14 patients, 79%) compared with those with extensive disease (7/19 patients, 37%) and among patients who were ambulatory prior to therapy (16/25 patients, 64%) compared with those who were nonambulatory (2/8 patients, 25%). Myelosuppression consisted primarily of neutropenia. Eight percent of the treatment courses in 29% of the patients were associated with hematuria and/or documented episodes of infection during neutropenia. There were three deaths possibly related to treatment, in two of which there was no evidence of disease at post-mortem examination. Six patients relapsed in the central nervous system (CNS). In four instances, CNS relapse was the only site of tumor progression. Central nervous system relapse was more common among evaluable patients who did not receive prophylactic brain irradiation (5/17 patients, 29%, vs. 1/15 patients, 7%; P . 0.23). The median survival duration for all patients was 63 weeks, being slightly longer for patients with limited disease than for those with extensive disease (70.9 weeks vs. 56 weeks; P . 0.18). This was also true for patients who achieved complete rather than partial remissions (71 weeks vs. 50 weeks; P . 0.09). Patients receiving prophylactic brain irradiation experienced longer survival (100.8 weeks vs. 48 weeks; P . 0.01).
- OSTI ID:
- 5577943
- Journal Information:
- Cancer (Philadelphia); (United States), Vol. 48:2
- Country of Publication:
- United States
- Language:
- English
Similar Records
Changes in the relative risk and sites of central nervous system metastasis with effective combined chemotherapy and radiation therapy for small cell carcinoma of the lung
Whole Neuraxis Irradiation to Address Central Nervous System Relapse in High-Risk Neuroblastoma
Related Subjects
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
59 BASIC BIOLOGICAL SCIENCES
CARCINOMAS
CHEMOTHERAPY
IMMUNOTHERAPY
CENTRAL NERVOUS SYSTEM
BIOLOGICAL RADIATION EFFECTS
RESPIRATORY SYSTEM DISEASES
CORYNEBACTERIUM PARVUM
DOXORUBICIN
EVALUATION
EXTERNAL IRRADIATION
ONCOVIN
PATIENTS
PREVENTIVE MEDICINE
SURVIVAL TIME
ALKALOIDS
ANTI-INFECTIVE AGENTS
ANTIBIOTICS
ANTIMITOTIC DRUGS
ANTINEOPLASTIC DRUGS
BACTERIA
BIOLOGICAL EFFECTS
DISEASES
DRUGS
IRRADIATION
MEDICINE
MICROORGANISMS
NEOPLASMS
NERVOUS SYSTEM
ORGANIC COMPOUNDS
RADIATION EFFECTS
THERAPY
550603* - Medicine- External Radiation in Therapy- (1980-)
560151 - Radiation Effects on Animals- Man
551000 - Physiological Systems
550200 - Biochemistry